Key facts
- This page summarizes Pascal Deschatelets's Form 4 filing for Apellis Pharmaceuticals, Inc. (APLS).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 10 Feb 2023, 16:00.
Pascal Deschatelets - 08 Feb 2023 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)
- Reporting relationship
- Chief Scientific Officer
- Issuer ticker
- APLS
- Reported as of
- 08 Feb 2023
- Net transaction value
- -$604,005
- SEC form
- 4
- Accepted by SEC
- 10 Feb 2023, 16:00:28 UTC
- Prior SEC filing
- 30 Jan 2023
- Next SEC filing
- 14 Feb 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ David Watson, attorney-in-fact for Pascal Deschatelets
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Pascal Deschatelets filed Form 4 for Apellis Pharmaceuticals, Inc. (APLS) on 10 Feb 2023.
Change
- Previous filing in this sequence was filed on 30 Jan 2023.
- Current net transaction value: -$604,005.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
APLS
transaction
Common Stock
Options Exercise
- Transaction value
- $49,395
- Shares
- +18,500
- Change %
- +1.8%
- Price
- $2.67*
- Shares after
- 1,018,756
- Date
- 08 Feb 2023
- Ownership
- Direct
- Footnotes
- F1
APLS
transaction
Common Stock
Sale
- Transaction value
- $653,400
- Shares
- -12,000
- Change %
- -1.2%
- Price
- $54.45
- Shares after
- 1,006,756
- Date
- 08 Feb 2023
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
APLS
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -18,500
- Change %
- -10%
- Price
- $0.000000
- Shares after
- 165,494
- Date
- 08 Feb 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 18,500
- Exercise price
- $2.67
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
This is a scheduled exercise and sale from a 10B5-1 trading plan.
Footnote F2
This stock option was granted on 12/5/2013 and is fully vested.